Ann: PharmAust makes Head of Manufacturing appointment, page-14

positions itself as a leading developer of neurodegenerative medicines.Dr Carol Worth will oversee the GMP manufacture of monepantel and the provision of clinical supplies
for our upcoming clinical studies. John Clark will lead global clinical operations as the Company
I wonder how this new Head of Manufacturing position differs to the appointment back in December 2023 of Dr Carol Worth as CMC Operations Manager?

“Dr Carol Worth will oversee the GMP manufacture of monepantel and the provision of clinical supplies for our upcoming clinical studies. John Clark will lead global clinical operations as the Company
positions itself as a leading developer of neurodegenerative medicines.”